Pesquisa | BVS Doenças Infecciosas e Parasitárias

1.

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Willekens, C; Rahme, R; Duchmann, M; Vidal, V; Saada, V; Broutin, S; Delahousse, J; Renneville, A; Marceau, A; Clappier, E; Uzunov, M; Rossignol, J; Pascal, L; Simon, L; Micol, J B; Pasquier, F; Raffoux, E; Preudhomme, C; Quivoron, C; Itzykson, R; Penard-Lacronique, V; Paci, A; Fenaux, P; Attar, E C; Frattini, M; Braun, T; Ades, L; De Botton, S.

Leuk Lymphoma ; 62(2): 438-445, 2021 02.

Artigo em Inglês | MEDLINE | ID: mdl-33043739

2.

Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.

Del Galy, A Sutra; Marouf, A; Raffoux, E; Robin, M; Michonneau, D; Sébert, M; de Fontebrune, F Sicre; Xhaard, A; Lengline, E; Itzykson, R; Frieri, C; Dombret, H; Fenaux, P; de Latour, R Peffault; Adès, L; Socié, G.

Leukemia ; 35(3): 934, 2021 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-33564086

3.

Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.

Del Galy, A Sutra; Marouf, A; Raffoux, E; Robin, M; Michonneau, D; Sébert, M; Sicre de Fontebrune, F; Xhaard, A; Lengline, E; Itzykson, R; Frieri, C; Dombret, H; Fenaux, P; Peffault de Latour, R; Adès, L; Socié, G.

Leukemia ; 35(1): 225-228, 2021 01.

Artigo em Inglês | MEDLINE | ID: mdl-32733010

4.

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

Patnaik, M M; Wassie, E A; Padron, E; Onida, F; Itzykson, R; Lasho, T L; Kosmider, O; Finke, C M; Hanson, C A; Ketterling, R P; Komrokji, R; Tefferi, A; Solary, E.

Blood Cancer J ; 5: e270, 2015 Jan 02.

Artigo em Inglês | MEDLINE | ID: mdl-25555161

5.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos, F; Thépot, S; Pleyer, L; Maurillo, L; Itzykson, R; Bargay, J; Stauder, R; Venditti, A; Seegers, V; Martínez-Robles, V; Burgstaller, S; Récher, C; Debén, G; Gaidano, G; Gardin, C; Musto, P; Greil, R; Sánchez-Guijo, F; Fenaux, P.

Leuk Res ; 39(3): 296-306, 2015 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-25601157

6.

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Padron, E; Garcia-Manero, G; Patnaik, M M; Itzykson, R; Lasho, T; Nazha, A; Rampal, R K; Sanchez, M E; Jabbour, E; Al Ali, N H; Thompson, Z; Colla, S; Fenaux, P; Kantarjian, H M; Killick, S; Sekeres, M A; List, A F; Onida, F; Komrokji, R S; Tefferi, A; Solary, E.

Blood Cancer J ; 5: e333, 2015 Jul 31.

Artigo em Inglês | MEDLINE | ID: mdl-26230957

7.

Epigenetics of myelodysplastic syndromes.

Itzykson, R; Fenaux, P.

Leukemia ; 28(3): 497-506, 2014 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-24247656

8.

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Patnaik, M M; Itzykson, R; Lasho, T L; Kosmider, O; Finke, C M; Hanson, C A; Knudson, R A; Ketterling, R P; Tefferi, A; Solary, E.

Leukemia ; 28(11): 2206-12, 2014 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-24695057

9.

An evolutionary perspective on chronic myelomonocytic leukemia.

Itzykson, R; Solary, E.

Leukemia ; 27(7): 1441-50, 2013 Jul.

Artigo em Inglês | MEDLINE | ID: mdl-23558522

10.

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

Kelaidi, C; Park, S; Sapena, R; Beyne-Rauzy, O; Coiteux, V; Vey, N; Stamatoullas, A; Choufi, B; Delaunay, J; Gourin, M-P; Cheze, S; Ravoet, C; Ferrant, A; Escoffre-Barbe, M; Aljassem, L; Raffoux, E; Itzykson, R; Adès, L; Dreyfus, F; Fenaux, P.

Leukemia ; 27(6): 1283-90, 2013 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-23370672

11.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Itzykson, R; Thépot, S; Beyne-Rauzy, O; Ame, S; Isnard, F; Dreyfus, F; Salanoubat, C; Taksin, A L; Chelgoum, Y; Berthon, C; Malfuson, J V; Legros, L; Vey, N; Turlure, P; Gardin, C; Boehrer, S; Ades, L; Fenaux, P.

Leuk Res ; 36(4): 397-400, 2012 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-22177456

12.

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

Duchmann, M; Braun, T; Micol, J-B; Platzbecker, U; Park, S; Pilorge, S; Beyne-Rauzy, O; Vey, N; Sébert, M; Gruson, B; Dumas, P-Y; Guieze, R; Chretien, M-L; Laribi, K; Chait, Y; Legros, L; Sahnes, L; Hirsch, P; Salanoubat, C; Solary, E; Fenaux, P; Itzykson, R.

Blood Cancer J ; 7(5): e562, 2017 05 12.

Artigo em Inglês | MEDLINE | ID: mdl-28498370

13.

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

Itzykson, R; Kosmider, O; Cluzeau, T; Mansat-De Mas, V; Dreyfus, F; Beyne-Rauzy, O; Quesnel, B; Vey, N; Gelsi-Boyer, V; Raynaud, S; Preudhomme, C; Adès, L; Fenaux, P; Fontenay, M.

Leukemia ; 25(7): 1147-52, 2011 Jul.

Artigo em Inglês | MEDLINE | ID: mdl-21494260

14.

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

Patnaik, M M; Wassie, E A; Padron, E; Onida, F; Itzykson, R; Lasho, T L; Kosmider, O; Finke, C M; Hanson, C A; Ketterling, R P; Komrokji, R; Tefferi, A; Solary, E.

Blood Cancer J ; 5: e280, 2015 Feb 13.

Artigo em Inglês | MEDLINE | ID: mdl-25679292

15.

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.

Itzykson, R; Ayari, S; Vassilief, D; Berger, E; Slama, B; Vey, N; Suarez, F; Beyne-Rauzy, O; Guerci, A; Cheze, S; Thomas, X; Stamatoullas, A; Gardembas, M; Bauduer, F; Kolb, A; Chaury, M C; Legros, L; Damaj, G; Chermat, F; Dreyfus, F; Fenaux, P; Ades, L.

Leukemia ; 23(4): 673-8, 2009 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-19151787

16.

Meeting report: myelodysplastic syndromes at ASH 2007.

Itzykson, R; Gardin, C; Fenaux, P.

Leukemia ; 22(5): 893-7, 2008 May.

Artigo em Inglês | MEDLINE | ID: mdl-18323798

17.

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

Kosmider, O; Itzykson, R; Chesnais, V; Lasho, T; Laborde, R; Knudson, R; Gauthier, A; Merlevede, J; Ades, L; Morabito, M; Fontenay, M; Tefferi, A; Droin, N; Solary, E.

Leukemia ; 27(9): 1946-9, 2013 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-23774674

18.

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Damm, F; Itzykson, R; Kosmider, O; Droin, N; Renneville, A; Chesnais, V; Gelsi-Boyer, V; de Botton, S; Vey, N; Preudhomme, C; Clavert, A; Delabesse, E; Park, S; Birnbaum, D; Fontenay, M; Bernard, O A; Solary, E.

Leukemia ; 27(6): 1401-3, 2013 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-23443343

19.

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.

Itzykson, R; Thépot, S; Eclache, V; Quesnel, B; Dreyfus, F; Beyne-Rauzy, O; Turlure, P; Vey, N; Recher, C; Boehrer, S; Gardin, C; Adès, L; Fenaux, P.

Leukemia ; 25(7): 1207-9, 2011 Jul.

Artigo em Inglês | MEDLINE | ID: mdl-21468040

BVS Doenças Infecciosas e Parasitárias

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.

Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Epigenetics of myelodysplastic syndromes.

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

An evolutionary perspective on chronic myelomonocytic leukemia.

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.

Meeting report: myelodysplastic syndromes at ASH 2007.

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.